Related Experiment Video

Updated: May 13, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Epidermal growth factor receptor inhibitors in non-small-cell lung cancer

Tina Cascone1, Erika Martinelli, Maria Pia Morelli

  • 1Cattedra di Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale 'F. Magrassi e A. Lanzara', Seconda Università degli Studi di Napoli, Naples, Italy.

Expert Opinion on Drug Discovery
|March 15, 2013
PubMed

Insights

Targeting the epidermal growth factor receptor (EGFR) offers a promising strategy for non-small-cell lung cancer (NSCLC) therapy. This review examines EGFR inhibitors, detailing their preclinical and clinical efficacy in treating NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The epidermal growth factor receptor (EGFR) is crucial in non-small-cell lung cancer (NSCLC) development and progression.
  • EGFR signaling pathways regulate cancer cell proliferation, apoptosis, angiogenesis, invasion, and metastasis.
  • EGFR is overexpressed in up to 80% of NSCLC cases, making it a key therapeutic target.

Purpose of the Study:

  • To review the preclinical and clinical results of EGFR inhibitors in NSCLC treatment.
  • To highlight the therapeutic potential of targeting the EGFR pathway in NSCLC.

Main Methods:

  • Review of preclinical data and clinical trial results for EGFR inhibitors.
  • Analysis of various EGFR-targeting agents, including small molecule tyrosine kinase inhibitors and monoclonal antibodies.

Main Results:

  • Several EGFR inhibitors, such as gefitinib, erlotinib, vandetanib, and cetuximab, have demonstrated promising activity in NSCLC patients.
  • These agents function as single agents or in combination with other anticancer modalities.

Conclusions:

  • Targeting EGFR is a valuable molecular approach for NSCLC therapy.
  • EGFR inhibitors show significant promise in the treatment of NSCLC.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: